Chiome Bioscience Inc.

4583

JP3205350006

Biotechnology & Medical Research

Delayed Japan Exchange Other stock markets 11:30:00 28/05/2024 am IST			5-day change	1st Jan Change
116 ^JPY	+2.65%		-6.45%	-14.07%

01/04	Chiome Bioscience Cancels License Agreements with ADC Therapeutics	MT
13/02	Chiome Bioscience Inc. Announces Entrustment Agreement with Takeda Pharmaceutical Company Limited	CI

Chiome Bioscience Inc. Provides Sales Guidance for the Year Ending December 31, 2020

November 10, 2020 at 12:30 pm IST

Chiome Bioscience Inc. provided sales guidance for the year Ending December 31, 2020. For the year, the company expects net sales to be ¥480 million.

Latest news about Chiome Bioscience Inc.

Chiome Bioscience Cancels License Agreements with ADC Therapeutics	01/04	MT
Chiome Bioscience Inc. Announces Entrustment Agreement with Takeda Pharmaceutical Company Limited	13/02	CI
Chiome Bioscience Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	13/02	CI
Chiome Bioscience Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023	14/11	CI
Chiome Bioscience Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	09/23/09	CI
Chiome Bioscience Inc. announced that it has received ¥13.49304 million in funding from Barclays Bank PLC (Tokyo Branch), Growth Capital, Inc.	20/23/20	CI
Chiome Bioscience Inc. announced that it expects to receive Â¥13.49304 million in funding	04/23/04	CI
Chiome Bioscience Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	11/23/11	CI
Chiome Bioscience Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	14/23/14	CI
Chiome Bioscience Inc. Provided Sales Guidance for 2023	14/23/14	CI
Henlius Biotech Terminates License Agreement for Chiome Bioscience's Tumor Drug	17/23/17	MT
Chiome Bioscience Inc. Announces Termination of the License Agreement for Anti-TROP-2 Antibody Development and Commercialization with Shanghai Henlius Biotech, Inc	17/23/17	CI
Chiome Bioscience Inc. Reports Earnings Results for the Nine Months Ended September 30, 2022	14/22/14	CI
Chiome Bioscience Reports Results of Cancer Immunotherapy Joint Research	09/22/09	MT
Chiome Bioscience Signs Research and Option Agreement with Heidelberg Pharma	14/22/14	MT
Heidelberg Pharma Enters Research Collaboration Deal With Japan's Chiome Bioscience	13/22/13	MT
Chiome Bioscience Inc. Announces Conclusion of Target-Specific Research and Option Agreement with Heidelberg Pharma	13/22/13	CI
Japan Index Snaps Three-day Winning Streak on Inflationary Pressures; Kudan Shares Expand 7%	12/22/12	MT
Chiome Bioscience, Rohto Pharmaceutical Sign Deal for Generation of Therapeutic Antibody	12/22/12	MT
Chiome Bioscience Inc. Announces Service Agreement with Option Contract with Rohto Pharmaceutical Co., Ltd	11/22/11	CI
Chiome Bioscience Inc. Announces First Patient in of Cancer Therapeutic Antibody CBA-1535 in A Phase 1 Clinical Trial	04/22/04	CI
Chiome Bioscience Details Progress of Phase I Study of Cancer Drug	14/22/14	MT
Chiome Bioscience Inc. Announces Conclusion of Contract with Additional Institutes and First Dosing of CBA-1205 in the Second Part of Phase 1 Study	13/22/13	CI
Japan Index Trims Gains over Inflationary Pressures; Dena to Take Majority Stake in Mobile ICT Business for $230 Million	27/22/27	MT
Chiome Bioscience, Kidswell Bio to Collaborate on Development of Cancer Antibody	27/22/27	MT

Chiome Bioscience Inc. is a company mainly engaged in the research and development of antibody drugs, and the provision of development support services. The Company operates in two business segments. The Drug Discovery segment is engaged in the research and development of specific antibodies based on new antigens and mechanisms and licensing to pharmaceutical companies. The Drug Discovery Support segment is engaged in development of lead antibodies for therapeutic drugs in collaborating with pharmaceutical companies in Japan and overseas.

Sector

Biotechnology & Medical Research

Calendar

07/08/2024 - Q2 2025 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
CHIOME BIOSCIENCE INC.	-14.07%	40.61M
MODERNA, INC.	+54.05%	63.85B
IQVIA HOLDINGS INC.	-2.02%	41.83B
LONZA GROUP AG	+40.01%	40.47B
CELLTRION, INC.	-10.22%	27.17B
ICON PUBLIC LIMITED COMPANY	+13.42%	26.52B
ALNYLAM PHARMACEUTICALS, INC.	-21.60%	18.69B
BIO-TECHNE CORPORATION	+2.89%	12.73B
UNITED THERAPEUTICS CORPORATION	+22.40%	12.11B
MEDPACE HOLDINGS, INC.	+27.49%	12.07B

Other Biotechnology & Medical Research